Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Meleagrin, a new FabI inhibitor from Penicillium chryosogenum with at least one additional mode of action.

PloS one - 1 Jan 2013

Zheng Chang Ji, Sohn Mi-Jin, Lee Sangku, Kim Won-Gon

Abstract excerpt

Bacterial enoyl-acyl carrier protein reductase (FabI) is a promising novel antibacterial target. We isolated a new class of FabI inhibitor from Penicillium chrysogenum, which produces various antibiotics, the mechanisms of some of them are unknown. The isolated FabI inhibitor was determined to be meleagrin by mass spectroscopy and nuclear magnetic resonance spectral analyses, and its more active and inactive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Bacterial Agents
Share to Biosynthetic Pathways
Share to Drug Evaluation, Preclinical

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Bacterial

Share to Enzyme Inhibitors

Share to Fatty Acids

Share to Microbial Sensitivity Tests

Share to Staphylococcus aureus

Source

Open in PubMed Open full text

Identifiers

PMID: 24312171
DOI: 10.1371/journal.pone.0078922
PMCID: PMC3842914

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Meleagrin, a new FabI inhibitor from Penicillium chryosogenum with at least one additional mode of action.PMID 24312171Read ↗

Fatty acid biosynthesis inhibitors fabimycin and triclosan trigger distinct resistance mutations in FabI and potently kill Gram-negative pathogensSemantic proximity Read ↗

Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK.Semantic proximity Read ↗

FabH mutations confer resistance to FabF-directed antibiotics in Staphylococcus aureus.Semantic proximity Read ↗

Environmental DNA-encoded antibiotics fasamycins A and B inhibit FabF in type II fatty acid biosynthesis.Semantic proximity Read ↗

Proteomic Signature of Fatty Acid Biosynthesis Inhibition Available for In Vivo Mechanism-of-Action StudiesSemantic proximity Read ↗

Antibacterial FabH Inhibitors with Mode of Action Validated in Haemophilus influenzae by in Vitro Resistance Mutation Mapping.Semantic proximity Read ↗

Validation of antibacterial mechanism of action using regulated antisense RNA expression in Staphylococcus aureus.Semantic proximity Read ↗

Inhibiting Bacterial Fatty Acid SynthesisSemantic proximity Read ↗

Discovery of Antibiotic ( <i>E</i> )-3-(3-Carboxyphenyl)-2-(4-cyanostyryl)quinazolin-4(3 <i>H</i> )-oneSemantic proximity Read ↗

The Burkholderia pseudomallei enoyl-acyl carrier protein reductase FabI1 is essential for in vivo growth and is the target of a novel chemotherapeutic with efficacy.Semantic proximity Read ↗

Unlocking Herbal Potentials: Novel Shikimate Kinase Inhibitors in the Fight Against Antibiotic ResistanceSemantic proximity Read ↗

Mutations upstream of fabI in triclosan resistant Staphylococcus aureus strains are associated with elevated fabI gene expression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.